P

P

LORD JESUS CHRIST SAYS

Matthew 22:37-40 Jesus said unto him, Thou shalt love the Lord thy God with all thy heart, and with all thy soul, and with all thy mind. This is the first and great commandment. And the second is like unto it, Thou shalt love thy neighbour as thyself. On these two commandments hang all the law and the prophets

7 Apr 2017

SHARE MARKET- WHAT IS THE FUTURE OF BIO-TECHNOLOGY IN INDIA.


Hi Friends,   The biotechnology sector of India is highly innovative and is on a strong growth trajectory.  The sector, with its immense growth potential, will continue to play a significant role as an innovative manufacturing hub.  The sector is one of the most significant sectors in  enhancing India’s global profile as well as contributing to the growth of the economy.
India is among the top 12 biotech destinations in the world and ranks third in the Asia-Pacific region.  India has the second-highest number of US Food and Drug Administration (USFDA) – approved plants, after the USA and is the largest producer of recombinant Hepatitis B vaccine.  Out of the top 10 biotech companies in India (by revenue), seven have expertise in bio-pharmaceuticals and three specialize in agri-biotech.  India has no dearth of talent in biotechnology, as a number of institutions, both government and autonomous, provide the necessary opportunities for the students seeking to obtain a degree in this sector.  The Government of India has provided adequate scope to this sector by providing facilities for Research and Development (R&D) in the field of biotechnology.

Market Size:  The Indian biotech industry holds about 2 per cent share of the global biotech industry.  The biotechnology industry in India, comprising about 800 companies, is growing at an average rate of about 20 per cent.  The Indian biotechnology sector is expected to grow from the current US$ 5-7 billion to US$ 100 billion by 2025, as per Union Minister for Science and Technology .
Bio pharma is the largest sector contributing about 64 per cent of the total revenue followed by bio services (18 per cent), bioagri (14 per cent), bio industry (3 percent), and bioinformatics contributing (1 per cent).  The high demand for different biotech products has also opened up scope for the foreign companies to set up base in India.
India has emerged as a leading destination for clinical trials, contract research and manufacturing activities owing to the growth in the bio services sector.

Investments:  India’s biotech sector has attracted significant amount of attention over the past two decades.  Several global companies have aggressively joined hands with Indian companies due to India’s strong generic biotechnology potential.  Some of the recent investments in this sector are as follows:
Shantha Biotechnics Private Limited has started building a facility to manufacture Insuman, an insulin product to treat diabetes.  French pharmaceutical company Sanofi SA, which acquired Shantha Biotechnics in 2009 through its vaccines division , Sanofi Pasteur SA , investing Rs.460 crore (US$ 69.31 MILLION) to build the facility that, at full capacity, will produce 60 million Insuman cartridges annually, company executives said.

Hyderabad headquartered vaccine manufacturer Indian Immunologicals Limited  (IIL), part of the National Dairy Development Board, is setting up a new vaccine manufacturing facility in Puducherry involving an investment of Rs.300 crore (US$ 45.20 million).  This is the fourth facility for IIL, which currently has two facilities in Hyderabad and one in Ooty.
Bristol Myers Squibb and Syngene International, the contract research subsidiary of Bicon Ltd. have announced a five-year extension of their drug discovery and development collaboration in India.

The Bhabha Atomic Research Centre (BARC) through its Centre for Incubation of Technologies (BARCIT) has signed a Memorandum of Understanding (MoU)  with M/s.  Veena Industries, Nagpur, for incubation of technology for biodegradable and edible films for food and pharmaceuticals packaging.

Aurobindo Pharma announced that its Board of Directors have approved the proposal for setting up a Joint Venture (JV) with Tergene Biotech, a vaccine development company based in India.   Tergene is currently working on development of  the Pneumococcal Conjugate Vaccine (PCV) through use of novel vaccine technology compressing time and cost, thereby making such vaccine available at an affordable cost.


India having about 380 biotech companies, of which 198 are in Karnataka with 191 in Bangalore alone.  There are several Indian states including Andhra Pradesh, Karnataka, Maharashtra, Himachal  Pradesh, Utter Pradesh, Kerala & Gujarat who have introduced additional financial and policy initiatives to encourage investment in biotechnology.
 

Good Luck.                                                         See You later.

No comments:

Post a Comment